TESAMORELIN — WHAT DOES IT DO?
Tesamorelin activates growth-hormone-releasing hormone receptors on pituitary cells. Those cells release growth hormone, which changes signals in other tissues and increases IGF-1.
Activates a pituitary receptor
Tesamorelin is an analog of growth-hormone-releasing hormone, or GHRH. It binds and stimulates GHRH receptors in the pituitary. [4]
Increases growth-hormone release
The receptor signal stimulates synthesis and release of growth hormone from pituitary cells. Its effects begin with this endocrine signal. [4]
How GHRH-receptor activation and the GH–IGF-1 axis influence visceral fat and metabolic biology.
What is Tesamorelin?
Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone. Its primary target is the GHRH receptor in the pituitary. It stimulates an existing hormonal pathway instead of acting as a direct fat-dissolving agent. [4]
Understanding the cellular focus.
The strongest clinical evidence selected here comes from adults with HIV-associated abdominal fat accumulation. Visceral fat sits around internal organs; subcutaneous fat lies under the skin. These are distinct measurements, and visceral-fat results should not be presented as general weight-loss results. [1][2]
What the studies found.
Selected original papers connect the mechanisms with measured findings. Open each source for its full methods and results.
Metabolic effects of a growth hormone-releasing factor in patients with HIV
In adults with HIV-associated abdominal fat accumulation, visceral adipose tissue decreased by 15.2% with tesamorelin and increased by 5.0% with placebo over 26 weeks. The paper also assessed lipids and IGF-1.
Read original source ↗Effects of tesamorelin in HIV-infected patients with excess abdominal fat: pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
The pooled analysis followed visceral-fat and metabolic outcomes, including extension data. It provides longer-duration context than a single short trial.
Read original source ↗Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
Measured reductions in visceral adipose tissue and liver fat compared with placebo. This directly studied tissue fat and metabolic outcomes in a defined clinical population.
Read original source ↗EGRIFTA SV — tesamorelin: pharmacology and safety findings
Describes pituitary GHRH-receptor activation and downstream GH/IGF-1 effects. Identifies elevated IGF-1, glucose intolerance or diabetes, fluid retention, hypersensitivity, malignancy-related concerns, and injection-site reactions as important safety issues.
Read original source ↗Human findings in context.
The 2007 trial recorded a 15.2% reduction in visceral fat with tesamorelin versus a 5.0% increase with placebo at 26 weeks. A later randomized study also measured liver-fat changes. These findings apply to the populations and formulations studied. Human data also identifies risks, including elevated IGF-1, glucose intolerance, fluid retention, and injection-site reactions. [1][3][4]
What the findings tell us.
Tesamorelin has defined human trial evidence and a defined endocrine target. Changes in visceral fat, body weight, liver fat, and glucose control are separate outcomes. The selected trials should not be used to promise every one of these outcomes in every setting.
A closer look at the evidence.
What does tesamorelin do at a cellular level?
It stimulates GHRH receptors on pituitary cells, increasing growth-hormone synthesis and release. GH then communicates with other tissues and increases IGF-1. [4]
Does tesamorelin directly break down fat?
Its primary action is hormonal signaling through the pituitary. Clinical trials measured changes in visceral fat downstream of that signal; they did not show that the peptide directly dissolves fat on contact. [1][4]
What risks has the human research identified?
Official prescribing information identifies elevated IGF-1, glucose intolerance or diabetes, fluid retention, hypersensitivity, malignancy-related concerns, and injection-site reactions. These are relevant research findings alongside the visceral-fat results. [4]